Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Part of paid clinical trials in Tucson, Arizona.

Sponsor
University of Arizona
Study ID
NCT04062565
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Pulmonary Arterial Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Treprostinil Injectable Product — DRUG
    Injection
  • Riociguat Pill — DRUG
    Tablet

Study Details

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

Key Dates

Start date
Mar 25, 2019
Status verified
Feb 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Treprostinil and Riociguat

Primary Outcome Measure

Change in stroke volume/end systolic volume (SV/ESV) [ Time Frame: Baseline to 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ArizonaTucsonArizona85724
Valerie Bloss, MS
[email protected]
520-626-8305
Franz Rischard, DO (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tucson, AZ

By research site
University of Arizona· Tucson, AZ

Related Studies